Praxis Precision Medicines's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.13 Mil. Praxis Precision Medicines's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.37 Mil. Praxis Precision Medicines's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $69.67 Mil.
Praxis Precision Medicines's debt to equity for the quarter that ended in Dec. 2023 was 0.04.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Praxis Precision Medicines's Debt-to-Equity or its related term are showing as below:
PRAX'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.04 Max: 0.05
Current: 0.04
During the past 6 years, the highest Debt-to-Equity Ratio of Praxis Precision Medicines was 0.05. The lowest was 0.00. And the median was 0.04.
Praxis Precision Medicines Debt-to-Equity Historical Data
The historical data trend for Praxis Precision Medicines's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Praxis Precision Medicines Annual Data
|
|
Trend |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
0.04 |
- |
0.02 |
0.05 |
0.04 |
|
Praxis Precision Medicines Quarterly Data
|
|
Dec18 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.05 |
0.05 |
0.03 |
0.03 |
0.04 |
Competitive Comparison
For the Biotechnology subindustry, Praxis Precision Medicines's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Praxis Precision Medicines Debt-to-Equity Distribution
For the Biotechnology industry and Healthcare sector, Praxis Precision Medicines's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Praxis Precision Medicines's Debt-to-Equity falls into.
Praxis Precision Medicines Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Praxis Precision Medicines's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Praxis Precision Medicines's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Praxis Precision Medicines (Praxis Precision Medicines) Business Description
Traded in Other Exchanges
N/A
Address
99 High Street, 30th Floor, Boston, MA, USA, 02110
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
Executives
| Jill Desimone |
director |
C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110 |
| Marcio Souza |
officer: Chief Executive Officer |
C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
| Dean J Mitchell |
director |
C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164 |
| Timothy Edwin Kelly |
officer: Chief Financial Officer |
C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142 |
| Lauren Mastrocola |
officer: Principal Accounting Officer |
C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142 |
| Alex Nemiroff |
officer: General Counsel and Secretary |
C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142 |
| Bsof Parallel Master Fund L.p. |
10 percent owner |
345 PARK AVENUE, NEW YORK NY 10154 |
| Merit Ester Cudkowicz |
director |
C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142 |
| Jeffrey Chodakewitz |
director |
C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL ST., SUITE 101, WATERTOWN MA 02472 |
| Stefan Vitorovic |
director |
C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142 |
| Blackstone Holdings I/ii Gp L.l.c. |
10 percent owner |
C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154 |
| William D Young |
director |
901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
| Stephen A Schwarzman |
10 percent owner |
C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154 |
| Blackstone Inc. |
10 percent owner |
345 PARK AVENUE, NEW YORK NY 10154 |
| Blackstone Group Management L.l.c. |
10 percent owner |
C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154 |
Praxis Precision Medicines (Praxis Precision Medicines) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRAX has been successfully added to your